Actively Recruiting
Evaluating Real-World Use and Outcomes of Upadacitinib in Adults with Inflammatory Bowel Disease in Belgium
Led by AbbVie · Updated on 2026-09-23
280
Participants Needed
11
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Crohns disease CD and ulcerative colitis UC are chronic inflammatory disorders affecting the gastrointestinal tract and colon, respectively. This research aims to assess the long-term effectiveness and safety of the drug upadacitinib in real-world clinical practice for adults with moderate to severe CD and UC. The study will observe participants prescribed upadacitinib according to local medical guidelines. Participants will receive upadacitinib as prescribed by their physicians based on routine clinical care and local label instructions. Approximately 280 adults across eight sites in Belgium will be enrolled. The treatment and monitoring will follow usual clinical practice without additional procedures imposed by the study. Participants will be followed for up to three years with regular visits at hospitals or clinics as part of their normal care. The research team will measure how many participants achieve clinical remission using specific scoring methods for UC and CD up to about 52 weeks. There is no expected extra burden beyond standard care during the study period.
CONDITIONS
Brief Title
Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium
Research Team
L
Liesbeth Ghys
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here